|
Active substance |
Brentuximab vedotin |
|
Holder |
Takeda Belgium |
|
Status |
Closed |
|
Indication |
in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for the treatment of adult patients with previously untreated systemic anaplastic cell lymphoma (sALCL) |
|
Public documents |
|
| Approbation amendment | |
|
Last update |
01/04/2021 |
Adcetris
Last updated on 07/11/2024